PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 24(4): 373-377 2004
© 2004 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Righetti, M
Right arrow Articles by Sessa, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Righetti, M
Right arrow Articles by Sessa, A
Peritoneal Dialysis International, Vol 24, Issue 4, 373-377
Copyright © 2004 by International Society for Peritoneal Dialysis

Clinical Trial

Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients

M Righetti, A Tommasi, C Lagona, L La Rosa, M Uccellini, and A Sessa

Division of Nephrology and Dialysis, Vimercate Hospital, Vimercate, Italy. nediavim@libero.it

BACKGROUND: Hyperhomocysteinemia, a risk factor for atherosclerosis, is frequently detected in patients with renal failure. Vitamin B supplementation reduces but rarely normalizes homocysteine (Hcy) levels in hemodialysis patients. There are no data about the effects of vitamin B therapy on Hcy levels in patients on peritoneal dialysis (PD). AIMS: We performed this trial both to observe baseline plasma Hcy levels in PD patients and to assess the effects of vitamin B therapy on Hcy levels in continuous ambulatory PD patients. METHODS: We conducted a 6-month prospective study of the effects of vitamin B therapy on plasma Hcy levels. Biochemical analyses were obtained at baseline and after every phase of treatment with folic acid, folic acid plus vitamin B12, and folic acid plus vitamin B12 plus vitamin B6. Eighteen of the 25 enrolled patients finished the study. RESULTS: Hyperhomocysteinemia was present in 83% of PD patients. We detected a trend toward a significant inverse relationship between baseline Hcy and folate levels. There were no significant correlations between baseline Hcy and vitamin B12, peritoneal membrane permeability, dialytic efficiency, or computed peritoneal Hcy clearance. We obtained an effective decrease in mean Hcy concentration from 20 to 14.8 micromol/L after folic acid and vitamin B12 treatment. We observed a further reduction in mean Hcy level to 12.8 micromol/L using the triple therapy; 72% of patients normalized their Hcy value. CONCLUSIONS: High doses of folic acid, vitamin B6, and vitamin B12 normalize Hcy values in the majority of PD patients. This treatment may be important in reducing cardiovascular morbidity and mortality.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Righetti
Hyperhomocysteinaemia and endothelial dysfunction in dialysis patients: what should be treated first?
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 1069 - 1069.
[Full Text] [PDF]

Home page
 J. Nutr.Home page
M. C. G. van de Poll, C. H. C. Dejong, and P. B. Soeters
Adequate Range for Sulfur-Containing Amino Acids and Biomarkers for Their Excess: Lessons from Enteral and Parenteral Nutrition
J. Nutr., June 1, 2006; 136(6): 1694S - 1700S.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. W. Mudge, R. Rogers, P. Hollett, B. Law, K. Reiger, J. J. B. Petrie, L. Price, D. W. Johnson, S. B. Campbell, N. M. Isbel, et al.
Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance
Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2178 - 2185.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2004 by Multimed Inc.